Study of a new combination drug for healthy volunteers
Part of Hormones & metabolism clinical trials.
This trial tests a new drug called AD-123 and compares it to taking two other drugs (AD-1231 and AD-1232) together. It is for healthy adults to see how the body handles the drugs and if they are safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy adult aged 19 or older.
- Your body mass index (BMI) is between 18 and 30.
- You have not taken part in another drug study in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how two experimental medications (AD-236A and AD-236B) interact with each other in the body and checks that they are safe for healthy adults. It helps determine how these drugs should be dosed for future treatments.
This trial tests a combination of three diabetes medicines (dapagliflozin, linagliptin, and metformin) in healthy adults to see how safe they are and how the body processes them. Participating could help make sure these medicines are safe for people with diabetes.
This study tests a new medicine called AD-231 and compares it to taking three separate pills together. You would need to be in generally good health and within a certain age and weight range.
This trial tests how three study drugs interact with each other in healthy adults. It may help find safe doses for future treatments.
This trial tests how two study drugs, AD-2321 and AD-2322, interact with each other in the body and checks if they are safe for healthy adults. Taking part will help researchers learn more about these drugs for future use.
This trial tests two forms of a new medicine to see how safe they are and how the body handles them. It is for healthy adults aged 19 to 64, and participation helps gather important early information before the drug is studied in patients.
Hear when a new Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.